Volume 15, Issue 2 (volume 15, number 2 2023)                   IJDO 2023, 15(2): 119-128 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Kheirkhah A H, Forouzani-Moghaddam M J, Afkhami-Ardekani M. Relationship between Probiotics and Type 2 Diabetes Mellitus: A Review. IJDO 2023; 15 (2) :119-128
URL: http://ijdo.ssu.ac.ir/article-1-795-en.html
Professor of Endocrinology, Diabetes Research Center, Shahid Sadougdi University of Medical Sciences, Yazd, Iran.
Abstract:   (163 Views)
Objective: Diabetes is a chronic medical condition that can be caused by either inherited or acquired insufficiency insulin secretion, or the body's inability to effectively utilize the insulin it produces. There are three primary classifications of diabetes: type 1, type 2, and gestational diabetes. Type 2 diabetes mellitus (T2DM) is characterized by elevated levels of fasting blood glucose (FBG) and glycosylated hemoglobin (HbA1c), indicating a disturbance in glucose metabolism. The term "probiotics" refers to living microorganisms that provide beneficial effects on the host's health. The effects of probiotics on T2DM in humans have shown conflicting results. Some studies have demonstrated that probiotic treatment substantially reduces HbA1c, FBG, or insulin resistance (IR) in patients with T2DM. However, other studies have found no significant difference between probiotic-treated patients and those receiving a placebo.. The use of probiotics was found to enhance glucose metabolism and HbA1c levels in individuals with T2DM. These findings are in line with previous reviews conducted on this topic.
Full-Text [PDF 465 kb]   (113 Downloads)    
Type of Study: Research | Subject: Special
Received: 2023/02/9 | Accepted: 2023/05/8 | Published: 2023/06/20

1. World Health Organization. World health statistics overview 2019: monitoring health for the SDGs, sustainable development goals. World Health Organization; 2019.
2. American Diabetes Association. Standards of medical care in diabetes-2009. Diabetes care. 2009;32(Suppl 1):S13.
3. Ahola AJ, Harjutsalo V, Forsblom C, Freese R, Mäkimattila S, Groop PH. The self-reported use of probiotics is associated with better glycaemic control and lower odds of metabolic syndrome and its components in type 1 diabetes. Journal of probiotics & health. 2017.
4. Jalali-KhanAbadi B, Yaghmaei P, Salmani MH, Afkhami Ardakani M. The effect of zinc supplemention on glycosylated hemoglobin in type II diabetic patients. Journal of Shahrekord University of Medical Sciences. 2011;12(4):58-63.(in Persian)
5. Ezoddini Ardakani F, Afkhami Ardakani M, Mohammadi Z, Sheikhha MH. Evaluating calcified carotid artery atheromas in panoramic radiographs of patients with type 2 diabetes mellitus. Oral Radiology. 2007;23:6-9.
6. Bommer C, Heesemann E, Sagalova V, Manne-Goehler J, Atun R, Bärnighausen T, Vollmer S. The global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study. The lancet Diabetes & endocrinology. 2017 ;5(6):423-30.
7. Seuring T, Archangelidi O, Suhrcke M. The economic costs of type 2 diabetes: a global systematic review. Pharmacoeconomics. 2015;33:811-31.
8. Akha O, Makhlough A, Khoddad T, Kharazm P. Evaluation of Microalbuminuria and its Related Risk Factors in Patients with Type II Diabetes Referred to Endocrinology Clinics in Sari, 2003-2009. Journal of Mazandaran University of Medical Sciences. 2013;23(107):12-8.
9. Xiang Y, Huang G, Shan Z, Pan L, Luo S, Yang L, et al. Glutamic acid decarboxylase autoantibodies are dominant but insufficient to identify most Chinese with adult-onset non-insulin requiring autoimmune diabetes: LADA China study 5. Acta diabetologica. 2015;52:1121-7.
10. Martinell M, Dorkhan M, Stålhammar J, Storm P, Groop L, Gustavsson C. Prevalence and risk factors for diabetic retinopathy at diagnosis (DRAD) in patients recently diagnosed with type 2 diabetes (T2D) or latent autoimmune diabetes in the adult (LADA). Journal of diabetes and its complications. 2016;30(8):1456-61.
11. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Medical clinics. 2004;88(4):787-835.
12. Horowitz M, Harding PE, Maddox AF, Wishart JM, Akkermans LM, Chatterton BE, et al. Gastric and oesophageal emptying in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1989;32:151-9.
13. Chang J, Rayner CK, Jones KL, Horowitz M. Diabetic gastroparesis-backwards and forwards. Journal of gastroenterology and hepatology. 2011;26:46-57.
14. Azpiroz F, Malagelada C. Diabetic neuropathy in the gut: pathogenesis and diagnosis. Diabetologia. 2016;59(3):404-8.
15. Wu SL. Staging of type 2 diabetes mellitus. Genetics and Molecular Research. 2015 Mar 20;14(1):2118-21.
16. Salgaço MK, Oliveira LG, Costa GN, Bianchi F, Sivieri K. Relationship between gut microbiota, probiotics, and type 2 diabetes mellitus. Applied microbiology and biotechnology. 2019;103:9229-38.
17. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D, Peng Y. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55-60.
18. Kobyliak N, Virchenko O, Falalyeyeva T. Pathophysiological role of host microbiota in the development of obesity. Nutrition journal. 2015;15:1-2.
19. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes research and clinical practice. 2018;138:271-81.
20. Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomi T, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. New England Journal of Medicine. 2008;359(21):2220-32.
21. Dugas LR, Lie L, Plange-Rhule J, Bedu-Addo K, Bovet P, Lambert EV, et al. Gut microbiota, short chain fatty acids, and obesity across the epidemiologic transition: the METS-Microbiome study protocol. BMC public health. 2018 Dec;18:1-0.
22. Bianchi F, Duque AL, Saad SM, Sivieri K. Gut microbiome approaches to treat obesity in humans. Applied microbiology and biotechnology. 2019;103:1081-94.
23. Gerritsen J, Smidt H, Rijkers GT, de Vos WM. Intestinal microbiota in human health and disease: the impact of probiotics. Genes & nutrition. 2011;6:209-40.
24. Swain MR, Anandharaj M, Ray RC, Rani RP. Fermented fruits and vegetables of Asia: a potential source of probiotics. Biotechnology research international. 2014;2014:250424.
25. Chilton SN, Burton JP, Reid G. Inclusion of fermented foods in food guides around the world. Nutrients. 2015;7(1):390-404.
26. Kothari D, Patel S, Kim SK. Probiotic supplements might not be universally-effective and safe: A review. Biomedicine & Pharmacotherapy. 2019;111:537-47.
27. Vergin F. Antibiotics and probiotics. Hippokrates. 1954;25(4):116-9.
28. Lilly DM, Stillwell RH. Probiotics: growth-promoting factors produced by microorganisms. Science. 1965;147(3659):747-8.
29. Tsuda H, Miyamoto T. Production of exopolysaccharide by Lactobacillus plantarum and the prebiotic activity of the exopolysaccharide. Food Science and Technology Research. 2010;16(1):87-92.
30. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature reviews Gastroenterology & hepatology. 2014;11(8):506-14.
31. Markowiak P, Śliżewska K. Effects of probiotics, prebiotics, and synbiotics on human health. Nutrients. 2017;9(9):1021.
32. Hotel AC, Cordoba A. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Prevention. 2001;5(1):1-0.
33. Rijkers GT, Bengmark S, Enck P, Haller D, Herz U, Kalliomaki M, Kudo S, Lenoir-Wijnkoop I, Mercenier A, Myllyluoma E, Rabot S. Guidance for substantiating the evidence for beneficial effects of probiotics: current status and recommendations for future research. The Journal of nutrition. 2010;140(3):671S-6S.
34. de Almada CN, Nunes de Almada C, Martinez RC, Sant'Ana AD. Characterization of the intestinal microbiota and its interaction with probiotics and health impacts. Applied Microbiology and Biotechnology. 2015;99:4175-99.
35. Pérez‐Sánchez T, Ruiz‐Zarzuela I, de Blas I, Balcázar JL. Probiotics in aquaculture: a current assessment. Reviews in Aquaculture. 2014;6(3):133-46.
36. Beck BR, Kim D, Jeon J, Lee SM, Kim HK, Kim OJ, et al. The effects of combined dietary probiotics Lactococcus lactis BFE920 and Lactobacillus plantarum FGL0001 on innate immunity and disease resistance in olive flounder (Paralichthys olivaceus). Fish & shellfish immunology. 2015;42(1):177-83.
37. Xia Y, Wang M, Gao F, Lu M, Chen G. Effects of dietary probiotic supplementation on the growth, gut health and disease resistance of juvenile Nile tilapia (Oreochromis niloticus). Animal Nutrition. 2020;6(1):69-79.
38. Liu W, Wang W, Ran C, He S, Yang Y, Zhou Z. Effects of dietary scFOS and lactobacilli on survival, growth, and disease resistance of hybrid tilapia. Aquaculture. 2017;470:50-5.
39. Chai PC, Song XL, Chen GF, Xu H, Huang J. Dietary supplementation of probiotic Bacillus PC465 isolated from the gut of Fenneropenaeus chinensis improves the health status and resistance of Litopenaeus vannamei against white spot syndrome virus. Fish & shellfish immunology. 2016;54:602-11.
40. Sun YZ, Yang HL, Ma RL, Song K, Lin WY. Molecular analysis of autochthonous microbiota along the digestive tract of juvenile grouper Epinephelus coioides following probiotic Bacillus pumilus administration. Journal of applied microbiology. 2011;110(4):1093-103.
41. Kechagia M, Basoulis D, Konstantopoulou S, Dimitriadi D, Gyftopoulou K, Skarmoutsou N, et al. Health benefits of probiotics: a review. International Scholarly Research Notices. 2013;2013.
42. Kobyliak N, Conte C, Cammarota G, Haley AP, Styriak I, Gaspar L, et al. Probiotics in prevention and treatment of obesity: a critical view. Nutrition & metabolism. 2016;13(1):1-3.
43. Toupin April K, Moher D, Stinson J, Byrne A, White M, Boon H, et al. Measurement properties of questionnaires assessing complementary and alternative medicine use in pediatrics: a systematic review. PLoS One. 2012;7(6):e39611.
44. Firouzi S, Majid HA, Ismail A, Kamaruddin NA, Barakatun-Nisak MY. Effect of multi-strain probiotics (multi-strain microbial cell preparation) on glycemic control and other diabetes-related outcomes in people with type 2 diabetes: a randomized controlled trial. European journal of nutrition. 2017;56:1535-50.
45. Khalili L, Alipour B, Jafar-Abadi MA, Faraji I, Hassanalilou T, Abbasi MM, et al. The effects of lactobacillus casei on glycemic response, serum sirtuin1 and fetuin-a levels in patients with type 2 diabetes mellitus: a randomized controlled trial. Iranian biomedical journal. 2019;23(1):68-77.
46. Mobini R, Tremaroli V, Ståhlman M, Karlsson F, Levin M, Ljungberg M, et al. Metabolic effects of L actobacillus reuteri DSM 17938 in people with type 2 diabetes: A randomized controlled trial. Diabetes, Obesity and Metabolism. 2017;19(4):579-89.
47. Razmpoosh E, Javadi A, Ejtahed HS, Mirmiran P, Javadi M, Yousefinejad A. The effect of probiotic supplementation on glycemic control and lipid profile in patients with type 2 diabetes: A randomized placebo controlled trial. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2019;13(1):175-82.
48. Tao YW, Gu YL, Mao XQ, Zhang L, Pei YF. Effects of probiotics on type II diabetes mellitus: a meta-analysis. Journal of translational medicine. 2020;18(1):1-1. [DOI:10.1186/s12967-020-02274-3]
49. Hoerr RA, Bostwick EF. Bioactive proteins and probiotic bacteria: modulators of nutritional health. Nutrition (Burbank, Los Angeles County, Calif.). 2000;16(7-8):711-3.
50. Karlsson FH, Tremaroli V, Nookaew I, Bergström G, Behre CJ, Fagerberg B, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;498(7452):99-103.
51. Brown K, DeCoffe D, Molcan E, Gibson DL. Diet-induced dysbiosis of the intestinal microbiota and the effects on immunity and disease. Nutrients. 2012;4(8):1095-119.
52. Kasińska MA, Drzewoski J. Effectiveness of probiotics in type 2 diabetes: a meta-analysis. Pol Arch Med Wewn. 2015;125(11):803-13.
53. Rios-Covian D, Gueimonde M, Duncan SH, Flint HJ, de Los Reyes-Gavilan CG. Enhanced butyrate formation by cross-feeding between Faecalibacterium prausnitzii and Bifidobacterium adolescentis. FEMS microbiology letters. 2015;362(21):fnv176.
54. Reichardt N, Duncan SH, Young P, Belenguer A, McWilliam Leitch C, et al. Phylogenetic distribution of three pathways for propionate production within the human gut microbiota. The ISME journal. 2014;8(6):1323-35. [DOI:10.1038/ismej.2014.14]
55. Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. Nature. 2012;489(7415):242-9.
56. Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 2012;61(2):364-71.
57. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. The Journal of clinical investigation. 2005;115(5):1111-9. [DOI:10.1172/JCI200525102]
58. De Vadder F, Kovatcheva-Datchary P, Goncalves D, Vinera J, Zitoun C, Duchampt A, et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell. 2014;156(1-2):84-96.
59. Medina-Vera I, Sanchez-Tapia M, Noriega-López L, Granados-Portillo O, Guevara-Cruz M, Flores-López A, Avila-Nava A, Fernández ML, Tovar AR, Torres N. A dietary intervention with functional foods reduces metabolic endotoxaemia and attenuates biochemical abnormalities by modifying faecal microbiota in people with type 2 diabetes. Diabetes & metabolism. 2019;45(2):122-31.
60. Vancamelbeke M, Vermeire S. The intestinal barrier: a fundamental role in health and disease. Expert review of gastroenterology & hepatology. 2017;11(9):821-34.
61. von Scholten BJ, Andresen EN, Sørensen TI, Jess T. Aetiological factors behind adipose tissue inflammation: an unexplored research area. Public health nutrition. 2013;16(1):27-35.
62. Wiesner P, Choi SH, Almazan F, Benner C, Huang W, Diehl CJ, et al. Low doses of LPS and minimally oxidized LDL cooperatively activate macrophages via NF-kappaB and AP-1: Possible mechanism for acceleration of atherosclerosis by subclinical endotoxemia. Circulation research. 2010;107(1):56.
63. Creely SJ, McTernan PG, Kusminski CM, Fisher FM, Da Silva NF, Khanolkar M, et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. American Journal of Physiology-Endocrinology and Metabolism. 2007;292(3):E740-7.
64. Trøseid M, Nestvold TK, Rudi K, Thoresen H, Nielsen EW, Lappegard KT. Plasma lipopolysaccharide is closely associated with glycemic control and abdominal obesity: evidence from bariatric surgery. Diabetes care. 2013;36(11):3627-32.
65. Kim YA, Keogh JB, Clifton PM. Probiotics, prebiotics, synbiotics and insulin sensitivity. Nutrition research reviews. 2018;31(1):35-51.
66. Yadav H, Jain S, Sinha PR. Oral administration of dahi containing probiotic Lactobacillus acidophilus and Lactobacillus casei delayed the progression of streptozotocin-induced diabetes in rats. Journal of Dairy Research. 2008;75(2):189-95.
67. Yadav H, Jain S, Sinha PR. Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats. Nutrition. 2007;23(1):62-8.
68. Ruan Y, Sun J, He J, Chen F, Chen R, Chen H. Effect of probiotics on glycemic control: a systematic review and meta-analysis of randomized, controlled trials. PloS one. 2015;10(7):e0132121.
69. Prawitt J, Caron S, Staels B. Bile acid metabolism and the pathogenesis of type 2 diabetes. Current diabetes reports. 2011;11:160-6.
70. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell metabolism. 2009;10(3):167-77.
71. Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon‐like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. 2011(10).
72. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. European cytokine network. 2006;17(1):4-12.
73. Borst SE. The role of TNF-α in insulin resistance. Endocrine. 2004;23:177-82.
74. Lin X, Zhang Z, Chen JM, Xu YY, Ye HR, Cui J, et al. Role of APN and TNF-α in type 2 diabetes mellitus complicated by nonalcoholic fatty liver disease. Genet. Mol. Res. 2015;14:2940-6.
75. Muoio DM, Newgard CB. Molecular and metabolic mechanisms of insulin resistance and β-cell failure in type 2 diabetes. Nature reviews Molecular cell biology. 2008;9(3):193-205.
76. Tonucci LB, Dos Santos KM, de Oliveira LL, Ribeiro SM, Martino HS. Clinical application of probiotics in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study. Clinical nutrition. 2017;36(1):85-92.
77. Wang S, Zhu H, Lu C, Kang Z, Luo Y, Feng L, et al. Fermented milk supplemented with probiotics and prebiotics can effectively alter the intestinal microbiota and immunity of host animals. Journal of Dairy Science. 2012;95(9):4813-22.
78. Hsieh FC, Lee CL, Chai CY, Chen WT, Lu YC, Wu CS. Oral administration of Lactobacillus reuteri GMNL-263 improves insulin resistance and ameliorates hepatic steatosis in high fructose-fed rats. Nutrition & metabolism. 2013;10:1-4.
79. Tiderencel KA, Hutcheon DA, Ziegler J. Probiotics for the treatment of type 2 diabetes: A review of randomized controlled trials. Diabetes/metabolism research and reviews. 2020;36(1):e3213.
80. Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi M, Mofid V. Probiotic yogurt improves antioxidant status in type 2 diabetic patients. Nutrition. 2012;28(5):539-43.
81. Asemi Z, Zare Z, Shakeri H, Sabihi SS, Esmaillzadeh A. Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative stress in patients with type 2 diabetes. Annals of nutrition and metabolism. 2013;63(1-2):1-9.
82. Mohamadshahi M, Veissi M, Haidari F, Shahbazian H, Kaydani GA, Mohammadi F. Effects of probiotic yogurt consumption on inflammatory biomarkers in patients with type 2 diabetes. BioImpacts: BI. 2014;4(2):83.
83. Ostadrahimi A, Taghizadeh A, Mobasseri M, Farrin N, Payahoo L, Gheshlaghi ZB, et al. Effect of probiotic fermented milk (kefir) on glycemic control and lipid profile in type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial. Iranian journal of public health. 2015;44(2):228.
84. Feizollahzadeh S, Ghiasvand R, Rezaei A, Khanahmad H, Sadeghi A, Hariri M. Effect of probiotic soy milk on serum levels of adiponectin, inflammatory mediators, lipid profile, and fasting blood glucose among patients with type II diabetes mellitus. Probiotics and antimicrobial proteins. 2017;9:41-7.
85. Kobyliak N, Falalyeyeva T, Mykhalchyshyn G, Kyriienko D, Komissarenko I. Effect of alive probiotic on insulin resistance in type 2 diabetes patients: randomized clinical trial. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2018;12(5):617-24.

Add your comments about this article : Your username or Email:

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Iranian Journal of Diabetes and Obesity

Designed & Developed by : Yektaweb